{"DataElement":{"publicId":"2974536","version":"1","preferredName":"Prior Vascular Endothelial Growth Factor Antibody Therapy Received Ind-2","preferredDefinition":"the yes/no indicator related to prior receiving of therapy that includes drugs which bind to vascular endothelial growth factor (VEGF) receptors without causing activation, thus blocking the production of new blood vessels and enhanced vessel permeability by the VEGF.","longName":"2974534v1.0:2018279v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2974534","version":"1","preferredName":"Prior Vascular Endothelial Growth Factor Antibody Therapy Received","preferredDefinition":"information related to prior receiving of therapy that includes drugs which bind to vascular endothelial growth factor (VEGF) receptors without causing activation, thus blocking the production of new blood vessels and enhanced vessel permeability by the VEGF.","longName":"2974532v1.0:2241679v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2974532","version":"1","preferredName":"Prior Vascular Endothelial Growth Factor Antibody Therapy","preferredDefinition":"Earlier in time or order.:A substance made by cells that stimulates new blood vessel formation.:(AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C20450:C16295:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Vascular Endothelial Growth Factor A","conceptCode":"C20450","definition":"Vascular endothelial growth factor A (232 aa, ~27 kDa) is encoded by the human VEGFA gene. This protein plays a role in both cell proliferation and angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BDBE138-D678-E625-E040-BB89AD437BFB","latestVersionIndicator":"Yes","beginDate":"2009-12-29","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-12-29","modifiedBy":"ONEDATA","dateModified":"2009-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241679","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-2368-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-09","modifiedBy":"ONEDATA","dateModified":"2005-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BDBE138-D686-E625-E040-BB89AD437BFB","latestVersionIndicator":"Yes","beginDate":"2009-12-29","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-12-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104897","version":"1","longName":"GOG-0250","context":"NRG"},{"publicId":"4104883","version":"1","longName":"GOG-0240","context":"NRG"},{"publicId":"4104917","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000174","version":"1","longName":"GOG-0262","context":"NRG"},{"publicId":"10000175","version":"1","longName":"GOG-0262","context":"NRG"}]}],"AlternateNames":[{"name":"2974534v1.0:2018279v1.0","type":"USED_BY","context":"NRG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Has the patient received prio","type":"Preferred Question Text","description":"Has the patient received prior therapy with any anti-VEGF drug, including Bevacizumab","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Has the patient received prior VEGF pathway-targeted agent such as bevacizumab, PTK787 or VEGF-trap?","url":null,"context":"CTEP"},{"name":"NRG_CRF text","type":"Alternate Question Text","description":"Has the patient received prior treatment affecting the VEGF/VEGFR pathway or the angiopoietin pathway in the recurrent setting (including, but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, pazopanib, cediranib, nintedanib and trebananib)?","url":null,"context":"NRG"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Prior VEGF-targeted therapy","url":null,"context":"Alliance"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has patient received prior therapy with more than one anti VEGF based agent (antibody or tyrosine kinase inhibitor)?*","url":null,"context":"COG"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7BDBE138-D698-E625-E040-BB89AD437BFB","latestVersionIndicator":"Yes","beginDate":"2009-12-29","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-12-29","modifiedBy":"TANGL","dateModified":"2020-02-11","changeDescription":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}